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Abstract: The treatment of children with cerebral palsy with Botulinum toxin A injections 
is well established, safe and effective. However, a standardized injection strategy is still 
missing  and  the  used  dosage  has  escalated  over  the  years.  In  the  recent  past,  the 
recommended dosages in Europe were, however, reduced due to a better understanding of 
the relationship between dosage, severe side effects and the kind of anesthesia used. To 
combine safety and efficacy, the trend tends to a lower dosage, but combined with a more 
specific  selection  of  injected  muscles.  The  treatment  of  these  key-muscles  takes  into 
account the best support for motor development to attain each individual motor milestone. 
Keywords: botulinum toxin A; cerebral palsy; CP; multi-level treatment; key-muscle concept 
 
1. Introduction 
1.1. Background 
The American orthopedic surgeon A.L. Koman first described the use of botulinum toxin A for the 
treatment of cerebral palsy (CP) in 1993 [1]. Since then therapy with botulinum neurotoxin type A 
(BoNT-A) has been established as an important pillar of treatment within the therapeutic options for 
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these patients. The therapy is regarded as safe and effective and, following adequate BoNT-A injection 
protocols, has been shown to lead to a reduction of surgical interventions [2]. It is currently considered 
to meet the criteria of evidence based medicine as a therapeutic option for treating spasticity in children 
and adults [3]. 
1.2. Rationale for BoNT-A Application 
The clinical symptoms of cerebral palsy (CP) are caused by non-progressive damage to the central 
nervous  system.  This  damage  is  permanent  but,  in  particular  during  growth,  its  effects  are  not 
unchanging. In Europe, in approximately 90% of the affected children this damage leads to the clinical 
symptoms  of  spastic  cerebral  palsy,  in  about  6%  to  the  dyskinetic  form  and  in  4%  to  the  ataxic 
form [4].  Direct  consequences  include,  in  addition  to  abnormal  muscle  tone,  the  loss  of  selective 
muscle  control  and  disturbance  of  physiological  balance  mechanisms  which  ultimately  lead  to 
limitation of motor development.  
As  secondary  consequences of  spasticity,  particularly  during  growth, structural contractures can 
occur  such  as  hip  and  knee  flexor  and  adductor  contractures  and  structurally  fixed  pes  equinus. 
Furthermore, alterations such as coxa antetorta, tibial torsion and pes planovalgus, summarized by the 
term  “lever  arm  diseases”,  as  well  as  spasticity-related  hip  luxation  and  subluxation  are  common 
resultant bony deformities. 
Based on its mechanism of action as an inhibitor of the release of acetylcholine, the use of BoNT-A 
is targeted at the reduction of spasticity. Contractures that are already structurally fixed can hardly be 
treated. Therefore, when deciding whether treatment with BoNT-A is indicated, it must be carefully 
differentiated  during  clinical  examination  between  dynamic  (spasticity)  and  structural  components 
(contracture) of movement limitation.  
In children with CP, the motor development involved in verticalisation and locomotion usually 
takes place before the age of seven years [5]. By the age of five about 60% of all children with total 
body involvement (bilateral spastic cerebral palsy of upper and lower extremities) reach the ability to 
walk, another 10% reach it by the age of ten [6]. Based on this data there is wide agreement that in 
order to promote functional gait early, BoNT-A application should be performed, i.e., beginning before 
the  age  of  six  years  [7].  Although  currently  available  clinical  studies  have,  at  best,  yielded  clear 
evidence for the successful treatment of spastic pes equinus and none at all for regimens including total 
lower and upper extremity treatment [8], the integration of BoNT-A therapy into a comprehensive 
treatment concept is generally required. In clinical routine, BoNT-A can be frequently integrated into 
existing treatment regimens when indicated according to current appropriate integrative patient and 
therapy management or multimodal therapy. Modifications of orthoses, physiotherapy, occupational 
therapy, medication, etc. may be necessary. Occupational therapy and physiotherapy play a special role 
since there will be improved therapeutic opportunities during the period from the effect of BoNT-A. Due 
to  the  reduction  of  spasticity,  a  “therapeutic  window”  for  treatment  in  general,  in  particular  the 
promotion of development and the prevention of contractures, is opened for this period. When treating 
children  their  social  settings  (family,  school/care  institution,  hobbies,  friends, etc.)  should  be 
particularly  taken  into  account.  Hence,  in  praxi  the  BoNT-A  therapist  must  maintain  close 
communication with associated disciplines as well as flexibility and pragmatism. However, to date Toxins 2010, 2  
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there is no uniform treatment strategy and the doses used have significantly varied over the years [9]. 
The increase in the total doses of Botox
® used, measured in units/kg body weight (BW), is shown in 
Figure 1. These total doses are not evidence based, but are based on “expert opinion”. Randomized, 
double-blind, placebo-controlled, dose-ranging studies such as the one from Baker et al. 2002 [10] are 
the rather rare exceptions concerning dose ranging studies with BoNT-A. 
Figure  1.  Reported/recommended  total  dose  of  Botox
®  for  the  treatment  of  infantile 
cerebral palsy by: (1) Koman et al. [1]; (2) Cosgrove et al. [11]; (3) Graham et al. [12];  
(4) Heinen et al. [13]; (5) Heinen et al. [14]. 
 
In the recent past, the recommended dosage in Europe was reduced due to a better understanding of 
the relationship between dosage, severe side effects and the kind of anesthesia used. 
Currently, within the clinical management of CP, the use of botulinum toxin is recommended to 
improve function and to support motor development [15]. 
1.3. Safety 
Severely affected CP patients (GMFCS Level V; [16]) are particularly prone to side effects. Organ 
systems of the patients that function within a compensatory status can decompensate as a result of 
slight  weakening,  which  might  cause  undesirable  effects  such  as  aspiration,  pneumonia  and 
asphyxia [17]. Considering data currently available, and the current discussion of serious side effects as 
a consequence of overdose [18–20], the manufacturers’ specifications (for Dysport
®) or conservative 
dosage  recommendations  (for  Botox
®;  [12])  should  be  complied  with,  in  particular  for  severely 
affected children. It has been suggested that sedation and anesthesia are also risk factors, in addition to 
the total dose [21].  
2. Previous Development 
Based on the results of instrumental gait analysis and differential clinical examination procedures, 
surgical treatment of CP has fundamentally changed in the past two decades and the necessity of early 
multi-level treatment is now taken into account. The concept being that, as far as possible, all muscle 
groups involved should be surgically treated in the same session [22]. Despite this, according to more 
recent publications, it must be borne in mind that the manifestation of spasticity significantly changes Toxins 2010, 2  
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during the growth period and that at around the age of 12 years, a reduction in spasticity can be 
expected [23]. The same authors also state that early selective treatment significantly reduces or even 
avoids the necessity for later multi-level treatment [24]. 
Analogously to multi-level surgical treatment, the spectrum of botulinum toxin therapy has been 
significantly widened with respect to the number of muscles or muscle groups treated.  
Over time the original single level injections for the treatment of pes equinus have been replaced by 
multi-level injections (e.g., M. gastrocnemius, medial knee flexors, adductors and M. psoas). 
High-Dose Multi-Level BoNT-A Therapy 
The ultimate aim of this therapy, for which there is no generally agreed procedure, is an optimum 
alignment  of  the  joints  of  the  lower  extremities  to  the  pelvis  by  a  treatment  series  analogous  to 
surgical treatment. 
This implies that if the distal muscles are exclusively involved then BoNT-A is only injected in 
these muscles. In children with more severe spasticity on the other hand each target muscle on each 
level should be injected. Through application of this regimen, the total dose for multi-level treatments 
of 2 to 6 muscle groups may be increased from 6 to 28 units per kg BW [25]. 
An  essential  part  of  multi-level  therapy  is  the  multimodal  treatment  approach.  Plaster  casts, 
physiotherapy and orthoses are particularly important. Treatment by plaster casts and functional and 
positioning orthoses in addition to physiotherapy is designed to improve longitudinal muscle growth 
and, thus, results in functional improvement. Within the scope of an integrated concept these options 
are combined to measurably increase the intensity and duration of the BoNT-A effect.  
To date, neither a standardization of this comprehensive multi-level concept exists nor may any 
clear conclusion be drawn from the presently available study data [8]. There are no studies concerning 
the ideal time to apply redression casts with regard to BoNT-A injection [26]. To avoid excessive 
inactivity atrophy of the non-spastic muscles, it is recommended that plaster casts be applied for no 
more than two weeks [7]. 
3. Key-Muscle Treatment 
This concept, which was introduced by the author in 1998 and has been used and developed further 
since  [27,28],  comprises  an  advanced  multimodal  therapeutic  approach  as  a  development  of  the  
high-dose multi-level concept. The therapy has been specified to better attend to the special qualities 
and complexity of CP. If children with CP reach a higher level of motor development, they benefit 
from what they have learned for a period of time measurably longer than the pharmacological effect of 
botulinum toxin persists. 
Generally speaking, children with CP have a risk of acquiring fixed contractures until the end of 
longitudinal growth. Hence, BoNT-A must stay available as a treatment option to these children for 
many years. Inadequate development of selective body control and balance due to abnormal muscle 
tone  being  the  primary  problems  of  spasticity  as  well  as  the  secondary  development of  structural 
contractures and bone deformities (lever arm diseases), must be considered when planning treatment. 
Due to the increasing structural contractures and bone deformities, with the decreasing effect of BoNT-
A in older children and adolescents for most children with cerebral palsy, surgery will be a preferred Toxins 2010, 2  
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option at some point in time. Despite that, a continuation of therapy with BoNT-A even after surgery 
seems reasonable to avoid recurrence of contractures.  
Therefore,  the  characteristics  of  therapy  have  to  be:  long-term  applicability,  sustainability, 
individual and flexible planning. This leads to good acceptance by parents and therapists and also takes 
motor development into account. A basic requirement for long-term treatment is the avoidance of 
secondary non-response and the formation of antibodies. Thus, within the context of the key-muscle 
concept,  multi-level  injections  are  performed  that  strictly  comply  with  well-proven  dosage 
recommendations (see below). 
For children with CP, motor development and motor learning are prolonged and difficult and there 
is a risk of long-term secondary changes. Therefore, the target of the key-muscle concept is to retain 
the  treatment  option  with  botulinum  toxin  for  as  long  as  possible,  ideally  during  the  entire 
development. In practice, the integration into a comprehensive interdisclipinary multimodal concept, 
including  intensive  physiotherapy,  occupational  therapy  and  orthoses,  is  essential. The key-muscle 
concept  presented  here  takes  these  elements  into  account  and  is  characterized  by  the  following 
four points:  
1. Treatment  goal:  reaching  the  next  motor  milestone,  the  next  stage  of  physiological  
motor development;  
2. Selection of the key-muscles;  
3. Early commencement of treatment;  
4. Long-term treatment option. 
3.1. Treatment Goal: Reaching the Next Motor Milestone 
The primary aim is to attain the next motor milestone with the prospective goal of verticalization 
and achieving the best possible locomotion. If a child reaches the ability to walk, the intention is to 
maintain, improve and optimize mobility. In case of stagnation on a lower motor level, the intention is 
to maintain, improve and optimize motor function on this level.  
The motor milestones have been defined according to Petö [29], the Gross Motor Function Measure 
(GMFM; [30]) and the WHO classification [31] as shown in Figure 2. 
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Figure  2.  Classification  of  levels  of  motor  development  (schematic)  as  applied  in  the  
key-muscle concept. 
 
3.2. Selection of the Key-Muscles 
Key-muscles are those muscles that, due to their spasticity, prevent attainment of the next motor 
milestone. Additionally, with respect to the key-muscle concept, muscles at acute risk for contracture 
or even muscles with initial contracture are injected. 
Spastic muscles do not have to be injected as long as the elevated tone does not impair function, there 
is no acute risk for developing contractures or, if the tone permits, compensatory mechanisms. 
3.3. Early Commencement of Treatment 
The rationale for starting treatment as early as possible is based on the finding that already in the 
first year  of motor development voluntary movements are organized around behavioral objectives. 
Children try out a combination of maneuvers to achieve a goal, thus learning new and more rapid 
movements and their coordination. To attain stable function, repetitive performance is necessary. In 
children with CP there may be an incorrect combination of movements. As a consequence, multiple 
repetitions lead to non-physiological learning, which results in non-physiological motor development 
or to the neglect of the affected extremity. It has been suggested that non-physiological movements 
lead to persisting effects in a developing brain [32]. During physiological development of the brain 
there is a progressive reduction of the cortical area activating motor function and hence an increase in 
the selective and specific control of movement [33]. After about one to two weeks, a brain lesion leads 
to hyperactivity of secondary ipsi- and contralateral motor areas which are, however, less numerous 
and less excitatory than the primary motor area [34]. A precondition for long-term improvement is the 
replacement of this secondary hyperactivity by activation of the primary stimulus, which is impossible 
in severe cases [35–37]. Furthermore, after several months deterioration, it is assumed to be due to 
inhibition of the affected motor area by the contralateral area [38]. Therefore, early improvement of the 
impaired motor function is plausible, and with an early commencement of treatment a great potential 
for development still exists. Non-physiological movement patterns are not learned in the first place, 
“dead ends” of motor development may be avoided. The importance of the first two years of life has to Toxins 2010, 2  
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be taken into account—in physiological development all five motor milestones are reached during this 
period of time. The first years of life are also important concerning spasticity-related hip lateralization 
and dislocation [39]. Sometimes not reaching the ability to play with the hands in supine position is 
noticed very early (highlighted in grey in Figure 2). In such cases, there is good experience with early 
reduction of the tone of the extensors and flexors of the forearm. The risk profile for the recommended 
doses for children under two years of age is not different from that of older children [40]. 
An early treatment of muscles prone to shortening helps to prevent fixed contractures so that the 
number and extent of later surgical interventions can be reduced [41]. Sufficient physiotherapeutic 
support is essential for the success of early treatment according to the key-muscle concept. Therefore, 
an out-patient neurological rehabilitation program known as Berlin Model [42] has been provided to 
our patients in recent years. 
3.4. Long-Term Treatment Option 
A basic requirement for the long-term treatment option is to avoid secondary non-response and 
formation of antibodies. Hence, within the context of the key-muscle concept multi-level injections are 
performed with strict adherence to proven dosage recommendations (for first injection of Dysport
®: 
20 units/kg BW,  subsequent injections: 10–30 units/kg  BW, total dose: max. 1000 units Dysport
® 
(European Marketing Authorization); for Botox
®: up to 12 units/kg BW, total dose: max. 300 units; [12]). 
4. Two Case Reports Exemplifying BoNT-A Therapy According to the Key-Muscle-Concept 
Two case reports BoNT-A Therapy according to the Key-Muscle-Concept are detailed in Figure 3 
and Figure 4. Figure 3 details the case of an 11 month-old girl with bilateral spastic cerebral palsy 
(diplegia) and Figure 4 shows a three year-old girl with right-sided unilateral spastic cerebral palsy. Toxins 2010, 2  
 
 
2265
Figure 3. Case example of early BoNT-A therapy: 11 months old girl with bilateral spastic 
cerebral palsy (diplegia). (a) At first presentation, spasticity in the entire lower extremity 
was seen. The clinical examination revealed pronounced catch of the hip flexors, adductors, 
hamstrings and a spastic pes equinus on both sides (Ashworth 2–4). The targeted motor 
milestone—the  ability  to  sit—could  not  be  achieved,  due  to  spastic  shortening  of  the 
hamstring muscles. Meeting the requirements of the key-muscle concept the hamstrings 
were  injected  with  70  units  Dysport
®  each  (total  dose  of  140  units  at  
7  kg BW,  20 units/kg BW respectively). (b) After 4 weeks of intensive physiotherapy 
according  to  the  Berlin  model  the  ability  to  sit  was  attained.  (c)  Sixteen  weeks  after  
BoNT-A injection, standing and walking sideways holding on to objects was possible. To 
improve  the  ability  to  stand  and  walk  both  Mm.  gastrocnemii  were  injected  to  assist 
plantigrade placement of the feet. (d) After another 16 weeks the patient could walk for a 
few meters  without aid. The clinical  examination still  showed reduced spasticity  when 
compared  to  the  previous  examinations,  hence  no  further  BoNT-A  injections  were 
performed. Intensive physiotherapy was continued and it was agreed that the patient would 
be presented again after another 8 weeks. 
 Toxins 2010, 2  
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Figure  4.  Case  example  of  specific selection  of the  key-muscles: 3  year old girl  with  
right-sided unilateral spastic cerebral palsy. (a) At first presentation, crawling as a motor 
milestone was impossible. The girl was able to roll from supine to prone position and vice 
versa with her right arm held in flexion due to spasticity. Hence, rolling was her form of 
moving  about.  No  speech  (not  even  single  words)  had  developed.  The  neuropediatric 
diagnosis was spastic hemiplegia with global retardation. Despite a multi-level BoNT-A 
injection,  elsewhere performed,  in the  lower  extremity,  and  physiotherapy on  a regular 
basis, no improvement of motor development was achieved. Two sections of the cranial 
MRI are shown in the bottom left. The clinical examination revealed pronounced catch of 
the  flexors,  as  well  as  the  extensors  of  the  right  upper  arm  (Ashworth  3).  Therefore,  
BoNT-A  was  injected  in  those  muscles  (30  units  of  Dysport
®  each)  and  intensified 
physiotherapy according to the Berlin model was started. To reach the motor milestone, 
crawling extension and weight-bearing of both arms is necessary and a treatment goal.  
(b) 6 months after injection and intensive physiotherapy the motor milestone crawling was 
achieved. Standing and walking sideways holding on to objects is possible with a spastic 
equinus and a compensatory recurvation of the knee on the right side, as well as trunk 
inclination for balance and stability. To further improve the ability to stand and walk, the 
right M. biceps brachii and the right M. gastrocnemius were injected with 30 and 100 units, 
respectively, of Dysport
® and physiotherapy continued. A planned visit 4 months later is 
omitted. (c) At the next presentation one year later the patient is able to walk without 
support. She had attended physiotherapy on a regular basis. The girl is now able to speak 
simple sentences. 
       Toxins 2010, 2  
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5. Conclusions for Practice 
Treatment of CP with Botulinum toxin is safe if the recommendations and guidelines for dosage are 
taken  into  account.  The  intermediate  to  long-term  treatment  results  depend  mainly  on  the  correct 
indication  and  integration  into  a  multimodal  management  concept,  which  has  to  include  all  other 
necessary treatment options such as orthoses, physiotherapy, occupational therapy, medication, etc. It is 
not a case of “either …or”, but “…as well as…”. To establish whether treatment with BoNT-A is 
indicated,  a detailed clinical analysis with differentiation of dynamic and structural components is 
essential  and  the  definition  of  a  treatment  goal  is  absolutely  necessary.  To  take  into  account  the 
patients’ changes during growth, injection therapy must be adaptable, thus, it should be performed 
flexibly and individually. To avoid antibody formation during long-term therapy, re-injection intervals 
should be at least three months.  
6. Keystones of the Own Procedure in Accordance with the Key-Muscle Concept 
6.1. Philosophy 
Long-term multi-level injection treatment with strict adherence to the dosage recommendations of 
the  company  Ipsen  (European  marketing  authorizations)  and  the  work  group  around 
Graham et al. [12]: 20 (initial dose) up to 30 units Dysport
®/kg/BW and up to 12 units Botox
®/kg/BW. 
6.2. Treatment Objective 
Individual  definition  of  management  regimen  for each patient, with optimum support of  motor 
development, taking into account the developmental level. Early commencement of treatment as soon 
as motor development, or attaining a level of motor development corresponding to age, seem to be 
impaired due to spasticity. 
6.3. Technique of Injection 
At the lower extremity one skin puncture and, if necessary (greater quantity), injection in a fan-
shaped pattern. Injections on an out-patient basis, if possible, so that the social settings of the children 
are interrupted as little as possible. Meticulous clinical orthopaedic examination to define the muscles 
to be injected (spastic muscles are easy to palpate without anesthesia; injection control of deep muscles 
or  of  muscles  difficult  to  palpate  using  ultrasound).  Best  possible  accuracy  of  injection  with  the 
premise that the child be affected as little as possible. General anesthesia only if absolutely necessary 
(e.g., for injecting the M. psoas). Minimum injection interval of at least three months. 
6.4. Injection Solution 
Use of a standard solution (500 units Dysport
® in 5 mL NaCl 0.9%, i.e., 100 units Dysport
® per 
1 mL or 100 units Botox
® in 2.5 mL NaCl 0.9%, i.e., 40 units Botox
® per 1 mL). Toxins 2010, 2  
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6.5. Multimodal Therapy 
Combination with physiotherapy, occupational therapy, orthoses, etc. (not either BoNT-A or other 
procedures, but BoNT-A and  other procedures). No use of redression casts in favor of corrective 
splinting and intensification of physiotherapy. 
6.6. Documentation 
Written documentation of findings and video documentation during each clinical examination. 
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